Within a newly established consortium, Immunetune will develop enhanced DNA vaccines against SARS-CoV-2 and other human coronaviruses. The vaccine is built on the combination of two strong synthetic vaccine platforms and the inclusion of conserved T and B cell epitopes to provide both humoral and cellular defenses against Covid-19 and possible future outbreaks of coronaviruses. The consortium is financially supported by Health Holland.
Important Regulatory Milestone achieved for Immunetune’s NeoVAC platform
Immunetune is proud to announce that they can continue their regulatory pathway, following supportive Scientific Advice from the Paul-Ehrlich Institute (PEI) in Germany on the 18th of June 2020.
